Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis

References

• Human rights: key facts. World Health Organization. 10 December 2022. [cited 2022 December 18]; Available from: https://www.who.int/news-room/fact-sheets/detail/human-rights-and-health#:~:text=The%20WHO%20Constitution%20(1946)%20envisages,acceptable%2C%20and%20affordable%20health%20care.
   Google Scholar
• World Bank Country and Lending Groups. Lower middle income economies. [cited 2022 March 1]; Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
   Google Scholar
• World Health Organization. Estimated DALYs (‘000) by cause, sex and WHO member state (1) 2016. [cited 2020 September 10]; Available from: www.who.int/healthinfo/global_burden_disease/GHE2016_DALYs-2016-country.xls?ua=1.
   Google Scholar
• World Bank. GDP per capita, PPP (constant 2017 international $) 2017. World Bank DataBank, World Development Indicators. [cited 2020 January 15]; Available from: http://databank.worldbank.org/data/source/world-development-indicators.
   Google Scholar
• Kanavos P, Tzouma V, Fontrier A-M, et al. Pharmaceutical pricing and reimbursement in the Middle East and North Africa region. A mapping for the current landscape and options for the future 2018 November. [cited 2019 December 2]; Available from: https://www.lse.ac.uk/business/consulting/assets/documents/pharmaceutical-pricing-and-reimbursement-in-the-middle-east-and-north-africa-region.pdf.
   Google Scholar
• Abdelaziz AB, Amor SH, Ayadi I, et al. Financing health care in Tunisia. Current state of health care expenditure and socialization prospects, on the road to Universal health coverage. La Tunisie Médicale. 2018;96(10/11):789–17.
   PubMedGoogle Scholar
• IQVIA June 2019 report on Middle East and Africa Pharmaceutical market insights thirteen edition. Analytical Timeframe: MAT Dec 2018. [cited 2020 March 11]; Available from: www.iqvia.com/-/media/iqvia/pdfs/mea/edition-13-mea-pharmaceutical-market-quarterly-report.pdf.
   Google Scholar
• World bank blog. [cited 2021 February 12]; Available from: https://blogs.worldbank.org/fr/arabvoices/dialogue-tunisia-pharmaceutical.
   Google Scholar
• Executive decree n° 20-326 of 6 Rabie Ethani 1442 corresponding to November 22, 2020 concerning the missions, composition, organization and functioning of the intersectoral economic committee of medicines. [cited 2021 February 12]; Available from: https://www.miph.gov.dz/fr/wp-content/uploads/2021/06/07-De%CC%81cret-exe%CC%81cutif-n%C2%B0-20-326.pdf.
   Google Scholar
• Ministerial Order of December 26, 2020 on the appointment of the chairman and members of the intersectoral economic committee of drugs. [cited 2021 October 25]; Available from: https://www.miph.gov.dz/fr/wp-content/uploads/2021/06/04-Arrete-du-26-decembre-2020-portant-designation-du-president-et-des-membres-du-comite-economique-intersectoriel-des-medicaments.pdf.
   Google Scholar
• Executive Decree No. 98-44 of February 1, 1998 on the ceiling margins applicable to the production, packaging and distribution of medicines for human medicine. [cited 2021 March 10]; Available from: https://www.joradp.dz/FTP/jo-francais/1998/F1998005.PDF.
   Google Scholar
• Decree n° 2-13-852 of 18th December 2013 sante.Gov.ma 2013. [cited 2023 February 25]; Available from: https://www.sante.gov.ma/Reglementation/TARIFICATION/2-13-852.pdf.
   Google Scholar
• Law No. 85-91 of 11/22/1985: regulating the manufacture and registration of drugs intended for human medicine as amended by Law No. 99-73 of July 26 1999. [cited 2021 June 12]; Available from: http://www.dpm.tn/images/pdf/texte/loi-85-91-consolide.pdf.
   Google Scholar
• Registration guide of the Directorate of Pharmacy and Medicines (DPM) of 2016. [cited 2019 December 11]; Available from: http://www.dpm.tn/images/pdf/guide_dpm.pdf.
   Google Scholar
• World Health OrganizationCountry pharmaceutical pricing policies: a handbook of case studies (‎March 2021)‎ 2021cited 2022 November 5]; Available from: https://apps.who.int/iris/handle/10665/341188.
   Google Scholar
• Decree N° 95-1142 of June 28, 1995 relating to products and services excluded from the regime of freedom of price and terms of their supervision. JORT. [cited 2022 February 2]; Available from: http://www.dpm.tn/images/pdf/texte/decret-95-1142.pdf.
   Google Scholar
• Order of the Minister of Health and the Minister of Commerce of March 27, 2020, amending the order of May 21, 1982, on the prices of pharmaceutical products. [cited 2022 February 2]; Available from: https://www.jurisitetunisie.com/download_jort.php?f=A2020_0581-F2020_027.pdf
   Google Scholar
• WHO. Maîtrise des coûts des médicaments importés/Etude de cas: Tunisie 2003. [cited 2021 February 4]; Available from: http://www.dpm.tn/images/pdf/maitrise_des_couts_tunisie.pdf.
   Google Scholar
• Order of 11 Joumada El Oula 1442 corresponding to December 26, 2020 setting the procedure for setting the prices of drugs by the intersectoral economic committee for drugs. [cited 2021 October 25]; Available from: https://www.miph.gov.dz/fr/wp-content/uploads/2021/06/05-Arrete-du-26-decembre-2020-fixant-la-procedure-de-fixation-des-prix-des-medicaments-par-le-comite-economique-intersectoriel-des-medicaments.pdf.
   Google Scholar
• Avis d’Evaluation des technologies de Santé - INEAS. Le trastuzumab dans le traitement du cancer du sein HER2 positif au stade précoce et localement avancé 2018. [cited 2022 February 25]; Available from: https://www.ineas.tn/sites/default/files/trastuzumab-ineas.pdf.
   Google Scholar
• Avis d’Evaluation des technologies de Santé - INEAS. SKYRIZI® (Risankizumab) dans le traitement du psoriasis en plaques modéré à sévère chez l’adulte 2022. Tunis: INEAS. [cited 2023 February 25]; Available from: https://www.ineas.tn/sites/default/files/SKYRIZI%20ETS%20INEAS.pdf.
   Google Scholar
• Choix méthodologiques pour les Etudes Pharmaco-Economiques - INEAS. n.d. [cited 2023 February 25]; Available from: https://www.ineas.tn/sites/default/files/ineas.hta_.guide_etudes_pharmacoeconomiques.pdf.
   Google Scholar
• Choix méthodologiques pour L’ANALYSE de L’IMAPCT Budgétaire a L’INEAS. n.d. [cited 2023 February 25]; Available from: https://www.ineas.tn/sites/default/files/ineas.hta_.guide_analyses_impact_budgetaire.pdf.
   Google Scholar
• Algérie presse service. Installation du comité intersectoriel des médicaments et de la commission d’homologation des dispositifs médicaux. [cited 2021 April 11]; Available from: https://www.aps.dz/sante-science-technologie/115586-installation-du-comite-intersectoriel-des-medicaments-et-de-la-commission-d-homologation-des-dispositifs-medicaux.
   Google Scholar
• Au Maroc , les prix de 1 258 médicaments vont baisser de 30 à 60 n.d. [cited 2023 February 25]; Available from: https://www.lequotidiendumedecin.fr/actus-medicales/medicament/au-maroc-les-prix-de-1-258-medicaments-vont-baisser-de-30-60.
   Google Scholar
• La Presse. Le secteur du médicament en Tunisie: les failles d’un système. [cited 2020 January 14]; Available from: https://lapresse.tn/9930/le-secteur-du-medicament-en-tunisie-les-failles-dun-systeme/#:~:text=Le%20syst%C3%A8me%20de%20compensation%20des,financier%20pour%20l’y%20aider.
   Google Scholar
• Algeria. Healthcare and Life sciences Review Pharmaboardroom February 2019. [cited 2020 May 16]; Available from: https://pharmaboardroom.com/country-reports/algeria-pharma-report-2019/.
   Google Scholar
• Nasreddine A. The Algerian pharmaceutical market; specifics and Characteristics. Revue des Etudes et Recherches en Logistique et Développement (RERLED). 1st ed. Vol. 1, Algeria: RERLED; 2020.
   Google Scholar
• Order of 23 Dhou El Hidja 1439 corresponding to September 3, 2018 amending and supplementing the order of March 6, 2008 setting the reference rates used as a basis for the reimbursement of drugs and the terms of their implementation. [cited 2022 October 25]; Available from: https://www.joradp.dz/FTP/JO-FRANCAIS/2018/F2018071.pdf.
   Google Scholar
• Order of 6 Safar 1434 corresponding to December 19, 2012 supplementing the order of March 6, 2008 establishing the list of medicines reimbursable by social security. [cited 2022 October 25]; Available from: https://www.m-culture.gov.dz/images/pdf/textes/2013/F2013026.pdf.
   Google Scholar
• Mobilising the health revenues to finance the health system in Morocco OECD. 2020. [cited 2021 December 11]; Available from: https://www.oecd.org/tax/tax-policy/mobilising-tax-revenues-to-finance-the-health-system-in-morocco.pdf.
   Google Scholar
• Comptes nationaux de la sante. Direction de la planification et des ressources financieres. Ministere de la sante. OMS 2018. [cited 2021 January 22]; Available from: https://www.sante.gov.ma/Publications/Etudes_enquete/Documents/2021/CNS-2018.pdf.
   Google Scholar
• WHO 2015: Morocco: Health Profile. Regional office for the Eastern Mediterranean, World Health Organization. 2015. [cited 2020 November]; Available from: https://apps.who.int/iris/handle/10665/253774.
   Google Scholar
• Commission d’évaluation économique et financière des produits de santé, internal regulations. National Health Insurance Agency, Kingdom Of Morocco, Mars. 2014. [cited 2020 August 3]; Available from: https://anam.ma/anam/wp-content/uploads/2021/11/Re-glement-Inte-rieur-CEEFPS.pdf.
   Google Scholar
• Transparency Commission. The National Health Insurance Agency. [cited 2020 August 3]; Available from: https://anam.ma/anam/commission-de-transparence/.
   Google Scholar
• Guide to reimbursable drugs ANAM. [cited 2021 March 3]; Available from: https://anam.ma/regulation/guide-medicaments/recherche-de-medicaments-par-nom/.
   Google Scholar
• UNICO studies series 4 consolidation and transparency: transforming tunisia’s health care for the poor. Washington DC: The World Bank, January 2013. Available from: https://documents1.worldbank.org/curated/en/242251468122347643/pdf/749970NWP0Box30Transparency0TUNISIA.pdf
   Google Scholar
• Khanfir M. How public policy could enable the knowledge economy: the case of healthcare sector in Tunisia. Tunisia Africa Business Council, January 2018. [cited 2021 January 12]; Available from: http://tabc.org.tn/wp-content/uploads/2018/11/Public-policy-to-enable-KBE-in-Africa.-The-case-of-Healthcare-sector-in-Tunisia.pdf.
   Google Scholar
• WHO, 2006: Tunisia: Health System Profile. Regional health systems observatory, World Health Organization 2006. [cited 2020 September 5]; Available from: https://www.ecoi.net/en/file/local/1017861/1228_1216908062_tunisia.pdf.
   Google Scholar
• WHO. Tunisia: medicine prices, availability, affordability and price components. Regional Office for the Eastern Mediterranean, World Health Organization. 2010. [cited 2020 August 15]; Available from: https://apps.who.int/iris/handle/10665/116638.
   Google Scholar
• Decree No. 2012-1709 of September 6, 2012, creating the national health accreditation body and setting its powers, administrative, scientific and financial organization, as well as the terms of its operation. [cited 2021 June]; Available from: http://www.atds.org.tn/Decretseptembre2012.pdf.
   Google Scholar
• Social Insured Area. Cnam. n.d. [cited 2022 March 3]; Available from: https://www.cnam.nat.tn/espace_assure.jsp.
   Google Scholar
• Abdel Rida N, Izham Mohamed Ibrahim M, Babar ZUD. Pharmaceutical pricing policies in Qatar and Lebanon: narrative review and document analysis. J Pharm Health Serv Res. 2019;10(3):277–287. doi: 10.1111/jphs.12304
   Google Scholar
• Tuck C, Maamri A, Chan AH, et al. Editorial: medicines pricing, access and safety in Morocco. Trop Med Int Health. 2019 March;24(3):260–263. doi: 10.1111/tmi.13191
   PubMed Web of Science ®Google Scholar
• Fradi H, Ghozzi N, Miled S, et al. An analysis of the Tunisian medicines price policy. Utrecht WHO Winter Meeting 2019. [cited 2022 February 12]; Available from: http://www.pharmaceuticalpolicy.nl/assets/uploads/2016/10/Programme-Winter-Meeting-report-2019.pdf.
   Google Scholar